366 related articles for article (PubMed ID: 12133397)
1. [Comparative study on two different dosages of conjugated equine estrogen continuously combined with medroxyprogesterone in prevention of postmenopausal osteoporosis].
Wu Y; Liu J; Xing S; Xu R; Zhang Z; Wang Y
Zhonghua Fu Chan Ke Za Zhi; 2002 May; 37(5):267-70. PubMed ID: 12133397
[TBL] [Abstract][Full Text] [Related]
2. A comparison of two different dosages of conjugated equine estrogen in continuous combined hormone replacement therapy with progestin.
Xing S; Wu Y; Liu J; Xu R; Zhang Z; Wang Y
Chin Med J (Engl); 2003 Apr; 116(4):584-7. PubMed ID: 12875727
[TBL] [Abstract][Full Text] [Related]
3. Effects of low-dose continuous combined conjugated estrogens and medroxyprogesterone acetate on menopausal symptoms, body weight, bone density, and metabolism in postmenopausal women.
Gambacciani M; Ciaponi M; Cappagli B; Genazzani AR
Am J Obstet Gynecol; 2001 Nov; 185(5):1180-5. PubMed ID: 11717654
[TBL] [Abstract][Full Text] [Related]
4. Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. Early Postmenopausal Intervention Cohort Study Group.
Hosking D; Chilvers CE; Christiansen C; Ravn P; Wasnich R; Ross P; McClung M; Balske A; Thompson D; Daley M; Yates AJ
N Engl J Med; 1998 Feb; 338(8):485-92. PubMed ID: 9443925
[TBL] [Abstract][Full Text] [Related]
5. Prevention of osteoporosis and uterine effects in postmenopausal women taking raloxifene for 5 years.
Jolly EE; Bjarnason NH; Neven P; Plouffe L; Johnston CC; Watts SD; Arnaud CD; Mason TM; Crans G; Akers R; Draper MW
Menopause; 2003; 10(4):337-44. PubMed ID: 12851517
[TBL] [Abstract][Full Text] [Related]
6. Percutaneous estrogen in prevention of early postmenopausal bone loss in Chinese women.
Sun A; Lin S; Yu W; Qin M; Chen F; Zhang Y; Wei Y; de Lignieres B
Chin Med J (Engl); 2002 Dec; 115(12):1790-5. PubMed ID: 12622925
[TBL] [Abstract][Full Text] [Related]
7. Prevention of postmenopausal bone loss with minimal uterine bleeding using low dose continuous estrogen/progestin therapy: a 2-year prospective study.
Mizunuma H; Okano H; Soda M; Kagami I; Miyamoto S; Tokizawa T; Honjo S; Ibuki Y
Maturitas; 1997 May; 27(1):69-76. PubMed ID: 9158080
[TBL] [Abstract][Full Text] [Related]
8. A randomized, open-label study of conjugated equine estrogens plus medroxyprogesterone acetate versus tibolone: effects on symptom control, bleeding pattern, lipid profile and tolerability.
Baracat EC; Barbosa IC; Giordano MG; Haidar MA; Marinho RM; Menegocci JC; Morais KM; Tomaz G; Wehba S
Climacteric; 2002 Mar; 5(1):60-9. PubMed ID: 11974560
[TBL] [Abstract][Full Text] [Related]
9. [Observation of preventing of bone loss during early postmenopause by percutaneous estradiol in Chinese postmenopausal women].
Sun A; Lin S; Wei Y
Zhonghua Fu Chan Ke Za Zhi; 2001 Jun; 36(6):348-51. PubMed ID: 11783133
[TBL] [Abstract][Full Text] [Related]
10. [The influence of hormonal replacement therapy on bone density in postmenopausal women depending on polymorphism of vitamin D receptor (VDR) and estrogen receptor (ER) genes].
Brodowska A
Ann Acad Med Stetin; 2003; 49():111-30. PubMed ID: 15552843
[TBL] [Abstract][Full Text] [Related]
11. Reduced vaginal bleeding in postmenopausal women who receive combined norethindrone acetate and low-dose ethinyl estradiol therapy versus combined conjugated equine estrogens and medroxyprogesterone acetate therapy.
Simon JA; Liu JH; Speroff L; Shumel BS; Symons JP
Am J Obstet Gynecol; 2003 Jan; 188(1):92-9. PubMed ID: 12548201
[TBL] [Abstract][Full Text] [Related]
12. Effects of two different regimens of continuous hormone replacement therapy on endometrial histopathology and postmenopausal uterine bleeding.
Yildirim G; Tugrul S; Uslu H; Pekin O; Eren S
Arch Gynecol Obstet; 2006 Feb; 273(5):268-73. PubMed ID: 16315025
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of low-dose estrogen and progestin therapy in postmenopausal women. A double-blind, prospective study of sequential versus continuous therapy.
Luciano AA; De Souza MJ; Roy MP; Schoenfeld MJ; Nulsen JC; Halvorson CV
J Reprod Med; 1993 Mar; 38(3):207-14. PubMed ID: 8487239
[TBL] [Abstract][Full Text] [Related]
14. A 10-year follow-up of the effect of continuous-combined hormone replacement therapy and its discontinuation on bone in postmenopausal women.
Heikkinen J; Vaheri R; Haapalahti J; Timonen U
Menopause Int; 2008 Jun; 14(2):70-7. PubMed ID: 18519268
[TBL] [Abstract][Full Text] [Related]
15. Different effects of oral conjugated equine estrogens and transdermal estrogen on undercarboxylated osteocalcin concentration in postmenopausal women.
Yasui T; Uemura H; Tomita J; Umino Y; Yamada M; Kuwahara A; Matsuzaki T; Maegawa M; Miura M; Irahara M
Menopause; 2006; 13(4):651-9. PubMed ID: 16837887
[TBL] [Abstract][Full Text] [Related]
16. Effects of hormone therapy on bone mineral density: results from the postmenopausal estrogen/progestin interventions (PEPI) trial. The Writing Group for the PEPI.
JAMA; 1996 Nov; 276(17):1389-96. PubMed ID: 8892713
[TBL] [Abstract][Full Text] [Related]
17. Effects of combined treatment with etidronate, nandrolone-decanoate and calcium on bone mineral density in postmenopausal women.
Bolanca S; Korsić M; Dekanić D; Cvijetić S
Acta Med Croatica; 1998; 52(3):159-63. PubMed ID: 9818438
[TBL] [Abstract][Full Text] [Related]
18. Effect of different preparations of hormone therapy on lipid and glucose metabolism, coagulation factors, and bone mineral density in overweight and obese postmenopausal women.
Osmanağaoğlu MA; Osmanağaoğlu S; Osmanağaoğlu T; Okumuş B; Bozkaya H
Fertil Steril; 2005 Aug; 84(2):384-93. PubMed ID: 16084879
[TBL] [Abstract][Full Text] [Related]
19. The differential effect of estrogen, estrogen-progestin and tibolone on coagulation inhibitors in postmenopausal women.
Keramaris NC; Christodoulakos GE; Lambrinoudaki IV; Dalamanga A; Alexandrou AP; Bramis J; Bastounis E; Creatsas GC
Climacteric; 2007 Oct; 10(5):400-7. PubMed ID: 17852143
[TBL] [Abstract][Full Text] [Related]
20. Long-term continuous combined hormone replacement therapy in the prevention of postmenopausal bone loss: a comparison of high- and low-dose estrogen-progestin regimens.
Heikkinen J; Vaheri R; Kainulainen P; Timonen U
Osteoporos Int; 2000; 11(11):929-37. PubMed ID: 11193245
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
